Why In News?
The import of Active Pharmaceutical Ingredients (APIs) from China a high-level update by Union Minister J.P. Nadda on March 10, 2026. While India's total API exports have successfully surpassed its imports in value, the country's reliance on Chinese volume has intensified, reaching a new high of 74%.
The "Pharmacy of the World" Paradox:
- India is the largest global manufacturer of generic medicines but remains critically dependent on China for raw materials.
- For specific life-saving antibiotics (Penicillin, Cephalosporins), dependency is as high as 80-100%.
Cost Efficiency Gap:
- Chinese APIs are often 20-30% cheaper due to massive economies of scale, integrated chemical clusters, and state subsidies.
Government Countermeasures:
- PLI Scheme for Bulk Drugs: With an outlay of ₹6,940 crore, it has successfully commissioned 38 projects covering 28 critical products as of December 2025.
- Import Substitution: India has started domestic production of 29 out of 43 formerly 100% imported "critical" APIs through the PLI initiative.
- Bulk Drug Parks: Dedicated parks are being established in Andhra Pradesh, Gujarat, and Himachal Pradesh with a ₹3,000 crore budget to reduce logistics and utility costs.
New Financial Support (Budget 2026):
- Biopharma SHAKTI: A new ₹10,000 crore initiative announced in the 2026 Union Budget to strengthen the domestic biopharmaceutical ecosystem and research capacity.
Market Outlook:
- The Indian API industry is projected to grow from $14.18 billion in 2025 to $22.18 billion by 2031.
Download Pdf
